Daclatasvir is marketed under the brand name Natdac and is classified as an antiviral drug used in combination therapy for chronic hepatitis c virus infection. It works by targeting a viral protein called ns5a, which the hepatitis c virus relies on to replicate its genetic material. By binding to ns5a, Natdac disrupts the formation of the replication complex and prevents the virus from producing new copies of its genome. The reduction in viral replication leads to lower levels of virus in the bloodstream, which can improve liver inflammation over time. This medication is typically administered orally once daily alongside other antivirals to achieve sustained virologic response. The overall effect is to suppress the infection and allow the liver to recover, offering a curative potential for many patients.

Natdac is a direct-acting antiviral medication used to treat chronic hepatitis c infection by inhibiting the ns5a protein. Its therapeutic role involves improving viral clearance and reducing liver inflammation in patients with genotype 1 or 4. The drug works by binding to the ns5a replication complex preventing the formation of functional viral rna replication intermediates. This interaction disrupts the viral life cycle and leads to impaired replication. Consequently antiviral efficacy is achieved with high rates of sustained virologic response across treated populations. The pharmacological profile demonstrates high potency and a favorable resistance barrier compared to older regimens.

Some patients may experience nausea or headache after taking Natdac. Fatigue and mild dizziness have also been reported infrequently. Liver enzyme levels can rise temporarily in a small number of cases. Skin reactions such as rash or itching are possible but usually mild. Swelling of the face or lips has been observed rarely and requires monitoring. Most side effects resolve without intervention and do not lead to long-term complications.

Natdac can cause common side effects such as headache and fatigue. Some patients may experience nausea or diarrhea during treatment. Less frequently, elevated liver enzymes or skin rash may occur. In rare cases, anemia or neutropenia have been reported. The medication may lead to insomnia or difficulty sleeping. Some individuals notice dry skin or mild itching of the limbs. Most side effects are mild and temporary, but any severe symptoms should be monitored closely.